1. Barai E, Nagy E, Kangas L, Berczi I (1996): Immunotherapy of the SL2–5 murine lymphoma with natural killer cells and Tamoxifen or Toremifene. In press, Cancer
2. Bogden AE, Keyes SR, Grant W, Silver M, Batista LI, LePage D (1995): Estrogen Sensitivity and the Therapeutic Benefit of Lanreotide Tamoxifen Combination in the Treatment of Breast Tumors. Proc AACR 36:523
3. Buzoni R, Biganzoli L, Bajetta E, Celio L, Fornasiero A, Mariani L, Zilemno N, Di Bartolomeo M, Di Leo A, Arcangeli G, Aitini E, Farina G, Schieppati GH, Galuzzo D, Marinetti A (1995): Combination Goserelin and Tamoxifen Therapy in Premenopausal Advanced Breast Cancer: a Multicentre Study by the ITMO Group.Brit J Cancer 71:1111–1114
4. Carthew P, Rich KJ, Martin EA, DeMattheis F, Lim CK, Manson MM, Festing FW, White IHN, Smith LL (1995): DNA damage as assessed by 32P- postlabelling in three rat strains exposed to dietary Tamoxifen. Carcinogenesis 16:1299–1305
5. Clarke R, van den Berg HW, Murphy RF (1990): Reduction of the Membrane Fluidity of Human Breast Cancer Cells by Tamoxifen and 17 beta-Estradiol. J Natl Cancer Inst 82:1702–1705